Abstract
Impacts of duloxetine combined with repetitive transcranial magnetic stimulation on neurotransmitters and cognitive function in patients with severe depression
  
DOI:
EN KeyWords: duloxetine  repetitive transcranial magnetic stimulation  major depressive disorder  neurotransmitter  cognitive function
Fund Project:河北省医学科学研究课题计划(20221652)
作者单位
马丽景 石家庄市第八医院功能科石家庄 050000 
杨赞琦 石家庄市第八医院功能科石家庄 050000 
张佳 石家庄市第八医院功能科石家庄 050000 
梁娟娟 石家庄市第八医院放射科石家庄 050000 
张硕 石家庄市第八医院放射科石家庄 050000 
徐曼华 石家庄市第八医院精神科石家庄 050000 
View Counts: 3497
PDF Download Counts: 4174
EN Abstract:
  Objective: To investigate the impacts of duloxetine combined with repetitive transcranial magnetic stimulation on neurotransmitter levels and cognitive function in patients with severe depression. Methods: A total of 200 patients with severe depression were randomly grouped into the control group and the combined group. The control group was treated with duloxetine hydrochloride enteric-coated capsules, and the combination group was treated with repeated transcranial magnetic stimulation on the basis of the control group. The curative effect and the cognitive function and neurotransmitter levels of the patients after treatment were compared between the two groups. Results: The total effective rate of combination group was higher than that of control group (P<0.05). The scores of Hamilton Depression Scale (HAMD) and repeatable battery for the asessment of neuropsychological status (RBANS) before and after treatment were significantly different between the two groups (P<0.05). After 6 weeks of treatment, HAMD scores in combination group were lower and RBANS scores were higher than those in control group (both P<0.05). The serum levels of gamma-aminobutyric acid (GABA), 5-hydroxytryptamine (5-HT) and dopamine (DA) in combination group were higher than those in control group, and there was no significant difference in the incidence of adverse reactions between the two groups. Conclusion: Duloxetine combined with repetitive transcranial magnetic stimulation can increase the levels of GABA, 5-HT, DA and other neurotransmitters in patients with severe depression, and improve cognitive function.
查看全文   Download PDF Reader  HTML Full Text
Close
本刊微信二维码